Name | amyloid beta-protein (human, 1-40) trifluoroacetate |
---|---|
Synonyms |
beta Amyloid (1-40) human
β-amyloid 40 Amyloid β-Peptide (1-40) (human) Amyloidb-Peptide(1-40)(human) amyloid β protein fragment 1-40 Abeta(1-40) β-amyloid protein 40 M.W. 4329.86 C194H295N53O58S AMYLOID B-PROTEIN FRAGMENT 1-40 SS-AMYLOID (1-40), RAT aβ40 H-Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-Leu-Val-Gly-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH Abeta40 Human β-amyloid peptide (1-40) β-Amyloid (1-40) |
Description | β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease. |
---|---|
Related Catalog | |
In Vitro | β-Amyloid (1-40) and (1-42) are major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF β-Amyloid (1-40) and (1-42) show a U-shaped natural course in normal aging[1].Chronic infusion of beta-amyloid (1-40) for 14 days into the rat cerebroventricle decreased the activity of soluble protein kinase C (PKC) in the hippocampus. Subcellular translocation of PKC to membrane fraction in hippocampal slices of rats treated with beta-amyloid (1-40) is completely abolished under acute stimulation with 0.5 microM phorbol-dibutyrate (PDBu)[2]. |
In Vivo | Chronic infusion of β-Amyloid (1-40) into rat cerebroventricle leads to deficit in spatial and non-spatial memory formation[2]. Chronic treatment of β-Amyloid (1-40) does not change lever-pressing performance significantly, but performance declined significantly 30 days after termination of the chronic daily regimen. The soluble unaggregated form of β-Amyloid (1-40), injected into the dorsal hippocampus, does not appear to have behavioral effects on performance or short-term working memory in rats, but multiple repeat injections produced performance decrements several weeks later. Repeated injection of β-Amyloid (1-40) through indwelling cannulae shows promise for development of an animal model of Alzheimer's disease[3]. |
Animal Admin | Rats: HPLC buffer insures the β-Amyloid (1-40) does not aggregate in solution prior to injection, β-Amyloid (1-40) and vehicle are bilaterally infused into the hippocampus, 20 min before experimental sessions, in volumes of 1, 2 and 3 μL per side, at a rate of <1 μL/min. Different volumes of the 1 μM solution are used. Volumes (doses) are given in random order and at least three sham-injection sessions are interposed between β-Amyloid (1-40) or vehicle injections. All rats receive all doses of β-Amyloid (1-40) under the acute injection regimen[3]. |
References |
Molecular Formula | C194H295N53O58S |
---|---|
Molecular Weight | 4329.867 |
Exact Mass | 4329.155 |
Appearance | powder | white |
Storage condition | −20°C |
Water Solubility | H2O: ~6 mg/mL |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |